How rapid-acting antidepressants (RAADs), such as ketamine, induce immediate and sustained improvements in mood in patients with major depressive disorder (MDD) is poorly understood. A core feature of MDD is the prevalence of cognitive processing biases associated with negative affective states, and the alleviation of negative affective biases may be an index of response to drug treatment....
Abstract Background Depression is a major global health challenge, affecting over 300 million people worldwide. Current pharmacological and psychotherapeutic interventions have limited efficacy, underscoring the need for novel approaches. Emerging evidence suggests that peak emotional experiences characterized by awe, transcendence, and meaning hold promise for rapidly shifting maladaptive...
Abstract Introduction N,N-Dimethyltryptamine (DMT), a naturally occurring psychedelic tryptamine contained in the indigenous ayahuasca brew has shown antidepressant effects. This Phase 2a clinical trial investigates for the first time the efficacy of isolated DMT in treatment-resistant depression (TRD). Methods Six TRD patients participated in an open-label, fixed-order, dose-escalation study,...
Objective:Ketamine has proved effective as a rapid-acting antidepressant agent, but treatment is not effective for everyone (approximately a quarter to a half of patients). Some adult studies have begun to investigate predictors of ketamine's antidepressant response, but no studies have examined this in adolescents with depression. Methods:We conducted a secondary data analysis of adolescents...
Abstract Background Ketamine is a novel and exciting putative antidepressant medication for patients with treatment-resistant depression. A complication commonly seen in frequent and heavy recreational use of ketamine is ulcerative cystitis, which presents with lower urinary tract symptoms (LUTS) and upper renal tract damage and can be seen in over 25% of regular users. Although...
AbstractBackgroundPersistent mind‐wandering processes are associated with negative emotions; however, mindful states exhibit an anticorrelation with mind‐wandering patterns. The aim of this study is to investigate the mediating role of excessive mind wandering (EMW), rumination, and trait mindfulness between attention‐deficit hyperactivity disorder (ADHD) symptoms and the severity of...
Objective: The present study aimed to determine the effectiveness of mindfulness-based intervention on sleep problems and depression in adolescents. Methods and Materials: This research was a quasi-experimental study with a pre-test and post-test design, along with a control group. The statistical population included all high school students with sleep problems in the city of Azarshahr during...
Objective: The aim of the present study was to examine the effectiveness of mindfulness-based cognitive therapy on self-blame and cognitive avoidance in adolescents with subclinical depression. Methods and Materials: This research utilized a quasi-experimental method with a pretest-posttest design and a control group. The statistical population of the present study consisted of all...
Following acute coronary syndrome (ACS), up to 40% of patients report elevated depressive symptoms which is associated with a two-fold increase in mortality risk due to behavioral and biological mechanisms. Mindfulness-Based Cognitive Therapy (MBCT) delivered via synchronous group videoconferencing could help reduce depressive symptoms. To guide MBCT adaptation for ACS patients for a future...
Treatment-resistant depression (TRD) is one of the most debilitating conditions that does not respond to conventional pharmacotherapy. Ketamine is a recently used effective treatment option in depressive disorders with a novel mechanism of action. Still, studies estimating the improvement of depressive symptoms in TRD with multiple doses of ketamine are limited. Hence, we report 5 TRD cases...
A Phase 3b open‐label trial has found that esketamine nasal spray in combination with an antidepressant was more efficacious than extended‐release quetiapine plus an antidepressant in patients with treatment‐resistant depression. Both patient groups experienced improved remission rates over time.
Background: Major depressive disorder (MDD) affects millions of people and is the leading cause of disability worldwide. Patients report decreased quality of life and ability to perform activities of daily living. It is estimated that the current standard of care, which includes pharmacologic therapy with a selective serotonin reuptake inhibitor, is effective in 40%–60%. Additional treatment...
Nitrous oxide has shown potentially as an efficacious intervention for treatment-resistant depression, yet there remains insufficient evidence pertaining to repeated administration of nitrous oxide over time and active placebo-controlled studies with optimal blinding. Thus, we aim to examine the feasibility and preliminary efficacy of a six-week follow up study examining the effects of a 4 week...
This study reports on 10 frontline healthcare workers, employed during the COVID-19 pandemic and experiencing symptoms of burnout and PTSD, treated with group ketamine-assisted psychotherapy (KAP) in a private outpatient clinic setting. Participants attended 6 sessions once weekly. These included 1 preparation session, 3 ketamine sessions (2 sublingual, 1 intramuscular), 2 integration sessions....
BACKGROUND Sleep disturbances are highly prevalent in depressive episodes and are linked to higher mood severity and suicidal behaviors. Slow wave sleep (SWS) and REM sleep are compromised in depression. Current evidence suggests that rapid antidepressant effects of intravenous (IV) ketamine in patients with treatment-resistant depression (TRD) is mediated by its effects on SWS and REM sleep....
Abnormal self-experiences are a common feature of major depression despite their absence from current diagnostic manuals. Current diagnostic criteria leave us with an impoverished conception of depressive disorders, and they fail to exploit the diverse experiential alterations that might be useful for understanding and diagnosing patients, and last but not least for explaining the aetiology of...
Depression is a debilitating mental health condition affecting millions worldwide. While antidepressant medications are widely prescribed, they often come with significant side effects and limited efficacy. Tessa Watford, a researcher in the field of neuroscience, has conducted a systematic review exploring the therapeutic potential of psilocybin, a naturally occurring psychedelic compound, for...
Depression, affecting over 264 million people globally, presents significant treatment challenges, often due to the limited efficacy and adverse effects of traditional antidepressants and the accessibility issues associated with psychotherapy. Recent advancements in psychedelic-assisted therapy, particularly using psilocybin, a naturally occurring compound found in “magic mushrooms”, shows...
Although the prognosis of ovarian cancer can be significantly improved through standardized surgery and chemotherapy, 70% of epithelial ovarian cancer (EOC) patients would suffer from drug resistance and recurrence during the long chemotherapy cycle. To explore the impact of a training mode based on the integration of virtual reality technology and mindfulness on anxiety, depression, and...
Various psychosocial interventions have been developed to reduce distress and improve quality of life (QoL) in patients with advanced cancer, many of which are traditional cognitive-behavioral interventions (CBIs) or mindfulness-based interventions (MBIs). The aims of this meta-analysis were to determine and compare the overall effects of traditional CBIs and MBIs on distress and QoL in this...